Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins

Cancer Research

Volumn 62, Issue 11, 2002, Pages 3264-3270

  El Hizawi, Sally ^a   Lagowski, James P ^a   Kulesz Martin, Molly ^a   Albor, Amador ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; MUTANT PROTEIN; PROTEIN P53; SPARFOSIC ACID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COLONY FORMATION; DOSE RESPONSE; ENZYME ACTIVATION; GENE AMPLIFICATION; GENETIC RECOMBINATION; GENETIC STABILITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

ASPARTIC ACID; BONE NEOPLASMS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MUTATION; OSTEOSARCOMA; PHENOTYPE; PHOSPHONOACETIC ACID; PROTEIN STRUCTURE, TERTIARY; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036605971     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. p53 and the development of genomic instability: Possible role of topoisomerase I interaction
2. Genetic instability in colorectal cancers
3. The complexity of p53 modulation - Emerging patterns from divergent signals
4. p53: Death star
5. Chromosome 17 deletions and p53 gene mutations in colonorectal carcinomas
6. p53 mutations in human cancers
7. Mutant p53 proteins bind DNA abnormally in vitro
8. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein
9. Dissociation of DNA binding and in vitro transcriptional activities dependent on the C terminus of p53 proteins
10. Oncogenic forms of p53 inhibit p53-regulated gene expression
11. Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells
12. Meth A fibrosarcoma cells express two transforming mutant p53 species
13. Gain-of-function mutations in the tumor suppressor gene p53
14. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness
15. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins
16. Reconstitution of p53 expression in a non-produce Ab-MuLV-transformed cell line by transfection of a functional p53 gene
17. Gain of function mutation in p53
18. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor α
19. Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: Evidence for a gain of function
20. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis
21. Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells
22. Modulation of DNA topoisomerase I activity by p53
23. p53 dependence of topoisomerase I recruitment in vivo
24. Wild type and mutant forms of p53 activate human topoisomerase I: A possible mechanism for the gain of function in mutants
25. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
26. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
27. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
28. Characterization of intra- and intermolecular DNA ligation mediated by eukaryotic topoisomerase I
29. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects
30. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff
31. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro
32. Mutagenic activity of topoisomerase I inhibitors
33. Molecular characterisation of camptothecin-induced mutations at the hprt locus in Chinese hamster cells
34. Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I
35. Camptothecin enhances random integration of transfected DNA into the genome of mammalian cells
36. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells
37. An immunodominant epitope on DNA topoisomerase I is conformational in nature - Heterogeneity in its recognition by systemic sclerosis sera
38. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
39. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin
40. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma
41. Human topoisomerase IIα and IIβ interact with the C-terminal region of p53
42. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
43. Structure of DNA formed in the first step of CAD gene amplification
44. c-myc overexpression and p53 loss cooperate to promote genomic instability
45. c-myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines
46. MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification
47. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: Aneuploidy and immortalization
48. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice
49. Abnormal centrosome amplification in the absence of p53
50. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
51. Genomic instability and apoptosis are frequent in p53 deficient young mice
52. DNA copy number amplifications in human neoplasms: Review of comparative genomic hybridization studies
53. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
54. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment
55. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors
56. Mutations in the p53 gene occur in diverse human tumour types
57. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
58. p53-catalyzed annealing of complementary single-stranded nucleic acids
59. The single-stranded DNA end-binding site of p53 coincides with the C-terminal regulatory region
60. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II
61. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription
62. Rational design of cytotoxic T-cell inhibitors